AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29804498 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis of fault attributions
Number of subjects: 154
Study 31869226 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 0
Study 31869226 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus model from the top three models
Number of subjects: 0
Study 31869226 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptor-based consensus model
Number of subjects: 0
Study 31869226 — intervention group
Group type: EXPERIMENTAL
Intervention: Local models for different ionization states
Number of subjects: 0
Study 31869226 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched molecular pair (MMP) analysis
Number of subjects: 0
Study 30669986 — intervention group
Group type: EXPERIMENTAL
Intervention: iSTEP mobile health intervention including Fitbit and text messages
Number of subjects: 20
Study 30669986 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to healthy diet
Number of subjects: 20
Study 30669986 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators for healthy diet
Number of subjects: 20
Study 28842733 — intervention group
Group type: COMPARATOR
Intervention: Low-dose KHCO3 (1 mmol/kg/day)
Number of subjects: 233
Study 28842733 — intervention group
Group type: COMPARATOR
Intervention: High-dose KHCO3 (1.5 mmol/kg/day)
Number of subjects: 233
Study 28842733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 27936845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing task with PM intention
Number of subjects: 0
Study 27936845 — intervention group
Group type: COMPARATOR
Intervention: Ongoing task alone
Number of subjects: 0
Study 27936845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing task with PM execution rewarded
Number of subjects: 0
Study 27936845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing task with minimized PM demands
Number of subjects: 0
Study 24086581 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education on antibiotic use delivered by a pharmacist (30-minute face-to-face session).
Number of subjects: 300
Study 24086581 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education on antibiotic use (intervention group).
Number of subjects: 300
Study 24086581 — intervention group
Group type: COMPARATOR
Intervention: Fever control (control group).
Number of subjects: 300
Study 21846460 — intervention group
Group type: EXPERIMENTAL
Intervention: FRP combined with metronidazole and amoxicillin
Number of subjects: 38
Study 21846460 — intervention group
Group type: EXPERIMENTAL
Intervention: FRP combined with doxycycline
Number of subjects: 38
Study 21846460 — intervention group
Group type: COMPARATOR
Intervention: FRP alone
Number of subjects: 38
Study 21846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic use of metronidazole and amoxicillin or doxycycline
Number of subjects: 38
Study 19125434 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment in severe pancreatitis
Number of subjects: 731
Study 17596104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat (25 mg, 50 mg, 75 mg with 150 mg loading dose, 100 mg, 150 mg, 200 mg)
Number of subjects: 48
Study 17596104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15238970 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits to a dental health educator over a 2-year period
Number of subjects: 271
Study 12964231 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla (lignocaine/prilocaine) anaesthetic cream
Number of subjects: 101
Study 12964231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 9807138 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel
Number of subjects: 60
Study 9807138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 7509495 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg risperidone
Number of subjects: 59
Study 7509495 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg risperidone
Number of subjects: 59
Study 7509495 — intervention group
Group type: COMPARATOR
Intervention: 400 mg clozapine
Number of subjects: 59
Study 2675953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 20
Study 2675953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2027 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (beta-adrenergic blockade)
Number of subjects: 21
Study 2027 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 21
Study 2027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-adrenergic blockade)
Number of subjects: 21
Study 31568286 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (5 U)
Number of subjects: 43
Study 31568286 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (control)
Number of subjects: 43
Study 28368334 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and fiber (HPHF; HP = 25 g, HF = 8 g)
Number of subjects: 20
Study 28368334 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein and high fiber (NPHF; NP = 12.5 g, HF = 8 g)
Number of subjects: 20
Study 28368334 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and normal fiber (HPNF; HP = 25 g, NF = 2 g)
Number of subjects: 20
Study 28368334 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein and fiber (NPNF; NP = 12.5 g, NF = 2 g)
Number of subjects: 20
Study 25752778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT, n=40)
Number of subjects: 95
Study 25752778 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT, n=55)
Number of subjects: 95
Study 23327614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate containing dialysate (A(+)D)
Number of subjects: 29
Study 23327614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate free citrate containing dialysate (A(-)D)
Number of subjects: 29
Study 21289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent book reading intervention in the NICU
Number of subjects: 116
Study 21289497 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control)
Number of subjects: 116
Study 20137328 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan and Felodipine together in the morning (Group A)
Number of subjects: 90
Study 20137328 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan in the morning and Felodipine in the evening (Group B)
Number of subjects: 90
Study 20137328 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine in the morning and Valsartan in the evening (Group C)
Number of subjects: 90
Study 16446323 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 43‐9006 (sorafenib) 400 mg orally twice daily
Number of subjects: 20
Study 16446323 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 43‐9006 (sorafenib)
Number of subjects: 20
Study 15542012 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory metronome pacing
Number of subjects: 12
Study 15542012 — intervention group
Group type: COMPARATOR
Intervention: Unassisted walking
Number of subjects: 12
Study 11376545 — intervention group
Group type: EXPERIMENTAL
Intervention: WAND local anesthetic delivery system
Number of subjects: 20
Study 9245041 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) at doses of 0.015, 0.25, 1.0, 2.0 micrograms/kg/min for 20 min each
Number of subjects: 12
Study 9245041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7994792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of Adriamycin (ADM) plus verapamil (VR) (30 mg/24 ml physiological saline + 15 mg/6 ml saline)
Number of subjects: 226
Study 7994792 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillation of Adriamycin (ADM) alone (30 mg/30 ml physiological saline)
Number of subjects: 226
Study 2838926 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU conventional heparin
Number of subjects: 9
Study 2838926 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 anti‐Xa U of low molecular weight heparin (Fragmin)
Number of subjects: 9
Study 2838926 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 9
Study 31863121 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote streaming support (RESS)
Number of subjects: 36
Study 31863121 — intervention group
Group type: COMPARATOR
Intervention: Conventional local support (LOS)
Number of subjects: 36
Study 31563369 — intervention group
Group type: EXPERIMENTAL
Intervention: smooth surface roller
Number of subjects: 36
Study 31563369 — intervention group
Group type: EXPERIMENTAL
Intervention: multilevel surface roller
Number of subjects: 36
Study 31563369 — intervention group
Group type: EXPERIMENTAL
Intervention: GRID surface roller
Number of subjects: 36
Study 28315878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 27
Study 28315878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 27
Study 28315878 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 27
Study 26165736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous proton pump inhibitor (PPI) before ESD
Number of subjects: 156
Study 26165736 — intervention group
Group type: COMPARATOR
Intervention: No intravenous proton pump inhibitor (PPI) before ESD
Number of subjects: 156
Study 23266658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness induction (11 minutes)
Number of subjects: 37
Study 23266658 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry induction (11 minutes)
Number of subjects: 37
Study 23266658 — intervention group
Group type: COMPARATOR
Intervention: Baseline (8 minutes)
Number of subjects: 37
Study 21943845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment (ART) initiated before 12 weeks
Number of subjects: 369
Study 21943845 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART initiated after immunological or clinical progression
Number of subjects: 369
Study 21943845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART for infants with CD4 count <25%
Number of subjects: 369
Study 18289229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate-adrenaline (1.8%, 0.76%, 1:200,000)
Number of subjects: 40
Study 18289229 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (0.5%)
Number of subjects: 40
Study 18289229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate-adrenaline
Number of subjects: 40
Study 18289229 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 40
Study 16483383 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and primary care interventions
Number of subjects: 10144
Study 14708412 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 60
Study 14708412 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone 8 mg
Number of subjects: 60
Study 14708412 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study 11024378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (AR)
Number of subjects: 104
Study 11024378 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 104
Study 9583652 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free worksite
Number of subjects: 8271
Study 8147235 — intervention group
Group type: EXPERIMENTAL
Intervention: GTD/EE
Number of subjects: 189
Study 8147235 — intervention group
Group type: COMPARATOR
Intervention: NGS/EE
Number of subjects: 189
Study 3310563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum activity of serum heat-stable lactate dehydrogenase (LD), analyzed every 12 hours for 48 to 108 hours
Number of subjects: 727
Study 3310563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum activity of aspartate aminotransferase (ASAT), analyzed once daily for 3 days
Number of subjects: 727
Study 3310563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum activity of creatine kinase (CK) and CK subunit B, analyzed every 6 hours for 48 hours
Number of subjects: 727
Study 31954063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation
Number of subjects: 211
Study 31954063 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 211
Study 30518470 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling by nurses over the telephone
Number of subjects: 261
Study 30518470 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation to screening colonoscopy
Number of subjects: 261
Study 26846612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 182
Study 26846612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy-based psychoeducation
Number of subjects: 182
Study 26846612 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 25902813 — intervention group
Group type: EXPERIMENTAL
Intervention: Early strategy: RRT initiated immediately
Number of subjects: 620
Study 25902813 — intervention group
Group type: COMPARATOR
Intervention: Delayed strategy: RRT initiated based on severity criteria
Number of subjects: 620
Study 23909846 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indometacin applied immediately post-PDT
Number of subjects: 35
Study 23909846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of l-NAME into 5-ALA-PDT-treated sites
Number of subjects: 35
Study 23909846 — intervention group
Group type: COMPARATOR
Intervention: 5-ALA-PDT
Number of subjects: 35
Study 23909846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal microdialysate sampling
Number of subjects: 35
Study 21568645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste containing fluoride
Number of subjects: 40
Study 21568645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste containing ACP
Number of subjects: 40
Study 21568645 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste containing both fluoride and ACP
Number of subjects: 40
Study 21568645 — intervention group
Group type: COMPARATOR
Intervention: Control (no active ingredients)
Number of subjects: 40
Study 18156521 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who read and signed the consent form accompanied by a family member/friend (intervention group, n = 70)
Number of subjects: 143
Study 18156521 — intervention group
Group type: COMPARATOR
Intervention: Participants who read and signed the consent form unaccompanied (control group, n = 73)
Number of subjects: 143
Study 16552410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement with 40 mg/day ephedra alkaloids and 100 mg/day caffeine
Number of subjects: 61
Study 16552410 — intervention group
Group type: COMPARATOR
Intervention: Control supplement
Number of subjects: 61
Study 16552410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement with ephedra and caffeine
Number of subjects: 61
Study 14559886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (aprepitant plus ondansetron and dexamethasone on day 1; aprepitant and dexamethasone on days 2 to 3; dexamethasone on day 4)
Number of subjects: 520
Study 14559886 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ondansetron and dexamethasone on day 1; dexamethasone on days 2 to 4)
Number of subjects: 520
Study 11106521 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 100
Study 11106521 — intervention group
Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 100
Study 8668804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced GRE T1-weighted MR imaging (0.10 mmol/kg) at 90 minutes
Number of subjects: 34
Study 8668804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced SE T1-weighted MR imaging (0.05 and 0.10 mmol/kg)
Number of subjects: 34
Study 8668804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA-enhanced SE and GRE T1-weighted MR imaging (0.05 and 0.10 mmol/kg)
Number of subjects: 34
Study 1421625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg b.i.d. for 10 days)
Number of subjects: 322
Study 1421625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg s.i.d. for 7 days)
Number of subjects: 322
Study 1421625 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin (600 mg s.i.d. for 7 days)
Number of subjects: 322
Study 1421625 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 7 days)
Number of subjects: 322
Study 1421625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg single dose)
Number of subjects: 322
Study 6496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 53
Study 6496357 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 53
Study 30315506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® Aura Gain™
Number of subjects: 50
Study 30315506 — intervention group
Group type: COMPARATOR
Intervention: Ambu® Aura Once™
Number of subjects: 50
Study 30089602 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg oral daily plus 500 mg intramuscular fulvestrant on day 1, 15, 29 and every 28 days thereafter
Number of subjects: 106
Study 30089602 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone 150 mg oral daily
Number of subjects: 106
Study 30089602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (fulvestrant + erlotinib) in EGFR wild type patients
Number of subjects: 106
Study 30089602 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone in EGFR wild type patients
Number of subjects: 106
Study 26727076 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.02, 0.04, 0.08, and 0.12 mg/kg)
Number of subjects: 34
Study 26727076 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.12 mg/kg)
Number of subjects: 34
Study 26727076 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0195‐0092
Number of subjects: 34
Study 26727076 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0195‐0092 (0.02 mg/kg and 0.04 mg/kg)
Number of subjects: 34
Study 26727076 — intervention group
Group type: COMPARATOR
Intervention: Norditropin NordiFlex
Number of subjects: 34
Study 24535604 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia (sufentanil bolus 10 μg when SPI > 50)
Number of subjects: 94
Study 24535604 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (sufentanil administered according to standard clinical practice)
Number of subjects: 94
Study 24535604 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-guided analgesia
Number of subjects: 94
Study 24535604 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 94
Study 22798536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,333 IU weekly
Number of subjects: 0
Study 22798536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20109743 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-standardized grass allergy immunotherapy tablet Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU)
Number of subjects: 257
Study 20109743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 18030118 — intervention group
Group type: COMPARATOR
Intervention: Medpor
Number of subjects: 10
Study 18030118 — intervention group
Group type: EXPERIMENTAL
Intervention: Medpor-Plus
Number of subjects: 10
Study 16124270 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducer size and distance
Number of subjects: 0
Study 12376782 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 50
Study 12376782 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 50
Study 10426855 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 0
Study 10426855 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting
Number of subjects: 0
Study 10426855 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization events
Number of subjects: 0
Study 7750333 — intervention group
Group type: EXPERIMENTAL
Intervention: Active B2 (salbutamol, 200 micrograms)
Number of subjects: 16
Study 7750333 — intervention group
Group type: COMPARATOR
Intervention: Placebo B2
Number of subjects: 16
Study 2405043 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 20
Study 2405043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2405043 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 20
Study 7016447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (2 puffs, equivalent to 1.0 mumol free base)
Number of subjects: 9
Study 7016447 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 puffs, equivalent to 1.6 mumol free base)
Number of subjects: 9
Study 7016447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30605991 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI group (Surgical Pleth Index guided analgesia)
Number of subjects: 140
Study 30605991 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional analgesia technique)
Number of subjects: 140
Study 30605991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 28352099 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-and-water handwashing
Number of subjects: 31
Study 28352099 — intervention group
Group type: COMPARATOR
Intervention: Water-only handwashing
Number of subjects: 31
Study 25955760 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HFS)
Number of subjects: 0
Study 25955760 — intervention group
Group type: COMPARATOR
Intervention: Frontal lessons only (Control)
Number of subjects: 0
Study 24160483 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly reminders for sit-to-stand activity
Number of subjects: 24
Study 24160483 — intervention group
Group type: COMPARATOR
Intervention: Reminders implemented every 3 months
Number of subjects: 24
Study 24160483 — intervention group
Group type: COMPARATOR
Intervention: Low intensity, paper-based reminders
Number of subjects: 24